| First-in-class rFVIII-Fc fusion protein. |
| Half-life ≈ 1.4−1.8 times that of conventional rFVIII products. |
| Efficacy and safety demonstrated in phase III clinical trials; effectiveness demonstrated in real-world studies. |
| Expected rate of inhibitor development in PUPs. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.